Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUST-III: taletrectinib versus crizotinib in untreated ROS1-positive advanced non-small cell lung cancer
CTR20243226Phase 3Active
- Sponsor
- AnHeart Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of taletrectinib, crizotinib in non-small cell lung cancer (NSCLC), sponsored by AnHeart Therapeutics. Started Nov 2024; status: active.
02
Drugs
taletrectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243226.